Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort

Shamar Young; Isa Cam; Mehmet Gencturk; Nathan Rubin; Donna D'souza; Siobhan Flanagan; Jafar Golzarian; Tina Sanghvi

doi:10.2147/JHC.S335183

Inflammatory Scores: Comparison and Utility in HCC Patients Undergoing Transarterial Chemoembolization in a North American Cohort

J Hepatocell Carcinoma. 2021 Dec 1:8:1513-1524. doi: 10.2147/JHC.S335183. eCollection 2021.

Authors

Shamar Young¹, Isa Cam¹, Mehmet Gencturk¹, Nathan Rubin², Donna D'souza¹, Siobhan Flanagan¹, Jafar Golzarian¹, Tina Sanghvi³

Affiliations

¹ University of Minnesota, Department of Radiology, Division of Interventional Radiology, Minneapolis, MN, 55455, USA.
² Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
³ Minneapolis VA Medical Center, Department of Radiology, Minneapolis, MN, USA.

Abstract

Background: The purpose of this study is to determine and compare the ability of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), aspartate-aminotransferase-to-lymphocyte ratio (ALRI), systemic-inflammation index (SII) and lymphocyte count to predict oncologic outcomes in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).

Materials and methods: A single-center retrospective review of 296 patients who were treated for 457 HCCs was performed. Pre- and post-treatment laboratory and treatment outcome variables were collected. Objective radiologic response (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Patients were categorized into above and below median scores and compared.

Results: The median pretreatment NLR, PLR, ALRI, SII, and lymphocyte count were 2.7 (range: 0.4-55), 88.3 (range: 0.1-840), 71.8 (range: 0.1-910), 238.1 (range: 0.1-5150.8), and 1 (range: 0.1-5.2) 10³/µL, respectively. Patients with above median ALRI scores were less likely to achieve an ORR as compared to those with below median ALRI values (132 (132/163, 81%) vs 150 (150/163, 92%), p = 0.004). On univariate analysis, patients with above median pretreatment NLR (HR 1.41, 95% CI: 1.09-1.83, p = 0.01) and below median lymphocyte count (HR 0.69, 95% CI: 0.53-0.92, p = 0.01) had significantly worse PFS. The relationship between PFS and NLR (p = 0.08) as well as lymphocytes (p = 0.20) no longer remained on multivariate analysis. On univariate analysis, below median pretreatment NLR (HR 1.72, 95% CI: 1.2-2.45, p = 0.003) and ALRI (HR 1.52, 95% CI: 1.05-2.2); p = 0.03) as well as above median lymphocyte count (HR 0.48, 95% CI: 0.34-0.7, p < 0.0001) were associated with improved OS. The significant relationship between lymphocytes and OS remained on multivariate analysis (HR 0.50, 95% CI: 0.28-0.9, p = 0.02), but the relationship with NLR (p = 0.94) did not persist.

Conclusion: NLR is predictive of PFS and OS in patients with HCC undergoing TACE and may be superior to other inflammatory scores (PLR, ALRI, and SII) in this setting. However, lymphocyte count may be most predictive of OS.

Keywords: aspartate-aminotransferase-to-lymphocyte ratio; chemoembolization; hepatocellular carcinoma; neutrophil-to-lymphocyte ratio; platelet-to-lymphocyte ratio; systemic-inflammation index.

Abstract

Grants and funding